Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
A recent analysis of an already CE-marked, AI-based system that identifies pneumothorax on chest radiographs revealed a weak point in what has largely been considered a reliable support tool.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Treating AFib with surgical ablation during mitral valve surgery and other common heart operations can help patients live longer, a new meta-analysis confirmed.
Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Palliative care is a recommended part of heart failure management in the U.S., but consultation rates remain low. The trend appears to impact Black patients more than other races and ethnicities.